Drug Trial Radar · NCT03939026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
May 1, 2019
Primary completion
Oct 23, 2021
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Conditions
- Relapsed/Refractory Large B Cell Lymphoma
- Relapsed/Refractory Follicular Lymphoma
Interventions
ALLO-501Genetic
ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501Time frame: 28 days
- Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501Time frame: 33 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Stanford University
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Moffitt Cancer Center
Tampa, Florida
Norton Cancer Institute
Louisville, Kentucky
St. Davids South Austin Medical Center
Austin, Texas
MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.